Abstract
Bacterial infections are a serious complication of hematologic malignancies and the therapies used to treat them. Neutropenia can result from the malignancy itself or develop as a complication of chemotherapy and remains a major risk factor for the development of infections in these patients. In addition, the mechanical and chemotherapeutic interventions applied to patients with hematologic malignancies impose additional challenges to host defenses against bacterial invasion. The bacteria responsible for most infections in this patient population have continued to evolve as different therapeutic, preventive, and preemptive strategies are introduced into the armamentarium for leukemias, lymphomas, and myelomas. Both Gram-negative and Gram-positive pathogens have become increasingly resistant to available antimicrobial agents, in part due to the increasing use of agents, especially the fluoroquinolones, to prevent bacterial infections. This review addresses recent clinical developments in the epidemiology and prevention of bacterial infections in these unique populations of patients.
Keywords: Hematologic malignancy, bacteria, epidemiology, prophylaxis, fluoroquinolone, armamentarium, leukemias, lymphomas, myelomas, Gram-negative, Gram positive pathogens, fluoroquinolones, neutropenia, yeast, mould, mucositis, hematopoietic stem cell transplantation (HSCT), Pseudomonas aeruginosa, Clostridium difficile, hepatobiliary infections, genitourinary infections, sinusitis, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Enterococcus faecium, Corynebacterium, empiric glycopeptide therapy, P. aeruginosa, Acinetobacter baumannii, neu-rotoxicity, nephrotoxicity, antimicrobial prophylaxis, Candida spp, Aspergillus spp, respiratory fluoroquinolones, moxifloxacin, Fluoroquinolone prophylaxis, catheter-related bloodstream infections
Infectious Disorders - Drug Targets
Title: Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies
Volume: 11 Issue: 1
Author(s): Jeffrey Tessier and Costi D. Sifri
Affiliation:
Keywords: Hematologic malignancy, bacteria, epidemiology, prophylaxis, fluoroquinolone, armamentarium, leukemias, lymphomas, myelomas, Gram-negative, Gram positive pathogens, fluoroquinolones, neutropenia, yeast, mould, mucositis, hematopoietic stem cell transplantation (HSCT), Pseudomonas aeruginosa, Clostridium difficile, hepatobiliary infections, genitourinary infections, sinusitis, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Enterococcus faecium, Corynebacterium, empiric glycopeptide therapy, P. aeruginosa, Acinetobacter baumannii, neu-rotoxicity, nephrotoxicity, antimicrobial prophylaxis, Candida spp, Aspergillus spp, respiratory fluoroquinolones, moxifloxacin, Fluoroquinolone prophylaxis, catheter-related bloodstream infections
Abstract: Bacterial infections are a serious complication of hematologic malignancies and the therapies used to treat them. Neutropenia can result from the malignancy itself or develop as a complication of chemotherapy and remains a major risk factor for the development of infections in these patients. In addition, the mechanical and chemotherapeutic interventions applied to patients with hematologic malignancies impose additional challenges to host defenses against bacterial invasion. The bacteria responsible for most infections in this patient population have continued to evolve as different therapeutic, preventive, and preemptive strategies are introduced into the armamentarium for leukemias, lymphomas, and myelomas. Both Gram-negative and Gram-positive pathogens have become increasingly resistant to available antimicrobial agents, in part due to the increasing use of agents, especially the fluoroquinolones, to prevent bacterial infections. This review addresses recent clinical developments in the epidemiology and prevention of bacterial infections in these unique populations of patients.
Export Options
About this article
Cite this article as:
Tessier Jeffrey and D. Sifri Costi, Epidemiology and Prevention of Bacterial Infections in Patients with Hematologic Malignancies, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407728
DOI https://dx.doi.org/10.2174/187152611794407728 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Pharmacogenetics of Asthma Therapy
Current Pharmaceutical Design Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Nanoparticles and Associated Toxicity
Current Nanoscience Modifying Toll-like Receptor 9 Signaling for Therapeutic Use
Mini-Reviews in Medicinal Chemistry Advances in the Development of Site-Specific Antibody-Drug Conjugation
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Serine Protease Inhibitors and T Lymphocyte Immunity
Current Immunology Reviews (Discontinued) Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Subject Index To Volume 9
Combinatorial Chemistry & High Throughput Screening Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
Current Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry